Type 2 diabetes is an important, independent risk factor for cardiovascular
disease. As a result of the pandemic explosion of Type 2 diabetes, reducin
g the human and financial consequences of the disease is a major healthcare
concern. In primary prevention, antihypertensive treatment, aspirin and li
pid-lowering intervention are effective at reducing the incidence of corona
ry heart disease although the beneficial effect of optimal glycaemic contro
l remains to be conclusively proven. Type 2 diabetic patients with acute my
ocardial infarction should receive a specific programme of intensive treatm
ent, which includes optimal glycaemic control using intensive insulin treat
ment, thrombolysis, and early use of beta-blockers and angiotensin-converti
ng enzyme inhibitors. Secondary prevention is also essential because beta-b
lockers and lipid interventions are more effective in Type 2 diabetic patie
nts than in non-diabetic patients with coronary artery disease. Unfortunate
ly, too many Type 2 diabetic patients do not receive adequate treatment or
do not comply with their long-term medical recommendations. (C) 1998 John W
iley & Sons, Ltd.